Sugi Predict

Sugi Predict / Compounds / SCHEMBL23043733

SCHEMBL23043733

SCHEMBL23043733

Cc1cc2c(cnn2C2CCCCO2)c(B2OC(C)(C)C(C)(C)O2)c1C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.39
▸ CYP4A11 Q02928 2/20 0.39
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ ATR Q13535 2/20 0.33
▸ PDE1A P54750 1/20 0.32
▸ PDE1B Q01064 1/20 0.32
▸ PDE1C Q14123 1/20 0.32
▸ DGAT2 Q96PD7 1/20 0.31
▸ RET P07949 1/20 0.31
▸ PARG Q86W56 1/20 0.30
▸ PDE9A O76083 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25795327 0.90 RXRA (0.40) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21243880 0.89 CYP4F2 (0.38) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29592576 0.89 CYP4F2 (0.40) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21243898 0.89 CYP4F2 (0.36) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29418904 0.89 CYP4F2 (0.36) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21379111 0.89 CYP4F2 (0.40) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL24536354 0.89 CYP4F2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29680540 0.89 CYP4F2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30959179 0.88 CYP4F2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31642270 0.88 CYP4F2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
EP-4735439-A1 KRAS INHIBITORS Bristol-Myers Squibb Company (US) 2026-05-06 — — EP disclosed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-12441727-B2 Tricyclic compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
US-12398154-B2 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2025-08-26 — — US disclosed
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 — — WO disclosed
EP-4581024-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS Jazz Pharmaceuticals Ireland Limited (IE) 2025-07-09 — — EP disclosed
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-06-12 — — US disclosed
EP-4548918-A2 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2025-05-07 — — EP disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed
CN-114615981-A KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2022-06-10 — — CN disclosed
WO-2022098625-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-05-12 — — WO disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 — — WO disclosed
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION 2021-11-18 — — US disclosed
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION 2021-11-18 — — US disclosed
WO-2021211864-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION (US) 2021-10-21 — — WO disclosed
WO-2021211864-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION (US) 2021-10-21 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441727-B2 Tricyclic compounds as inhibitors of KRAS KRAS, NRAS, HRAS CYP4F2 2855/4885CYP4A11 2783/4885RXRA 3045/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS CYP4F2 3406/4885CYP4A11 1064/4885RXRA 4205/4885
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS CYP4F2 2828/4885CYP4A11 2524/4885RXRA 3260/4885
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS KRAS, NRAS, HRAS CYP4F2 2545/4885CYP4A11 2241/4885RXRA 3493/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS CYP4F2 2700/4885CYP4A11 1337/4885RXRA 2150/4885
US-12398154-B2 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS CYP4F2 3798/4885CYP4A11 1809/4885RXRA 2519/4885
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS CYP4F2 2888/4885CYP4A11 1395/4885RXRA 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.